The market continues to stress the company's exposure to OpenAI, not least as Oracle's debt continues to balloon while its ...
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results